Search clinical trials for: 10E8.4/iMab

Total 271 results

Bristol-Myers Squibb

Terminated

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Cancer | Neoplasm | Tumors | Malignancy

United States, Canada, Spain, Switzerland
Emory University
Celgene Corporation

Terminated

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
CanariaBio Inc.
Korean Cancer Study Group

Recruiting

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer by FIGO Stage

Korea, Republic of
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; PPD; Rho Federal Systems Division, Inc.; Immune Tolerance...

Recruiting

Daratumumab and Belatacept for Desensitization (ATTAIN)

Highly Sensitized Prospective Kidney Transplant Recipients

United States
New Approaches to Neuroblastoma Therapy Consortium
United Therapeutics

Active, not recruiting

MIBG With Dinutuximab +/- Vorinostat

Neuroblastoma

United States
Rutgers, The State University of New Jersey
National Institute on Drug Abuse (NIDA)

Completed

Developing a Smoking Cessation Intervention for Methadone Maintained Smokers

Nicotine Dependence | Opiate Dependence

United States
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Asthma

United States
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Duke University
National Institute of Mental Health (NIMH)

Completed

Antidepressant Safety in Kids Study (ASK)

Obsessive Compulsive Disorder | Anxiety Disorders | Eating Disorders | Depressive Disorders

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Stand Up To Cancer; Aduro Biotech, Inc.; American Association... and other collaborators

Completed

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

Previously Treated Metastatic Adenocarcinoma of the Pancreas

United States
Genmab
AbbVie

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Belgium, Brazil, China, United States, Canada and more
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Metastatic Pancreatic Adenocarcinoma

United States
Zahedan University of Medical Sciences

Completed

Evaluation of the Success Rate of Pulpal Anesthesia in Mandibular First Molar Following Infiltration of 4% Articaine Alone and as Supplemental Injection After Inferior Alveolar Nerve Block

Pulpal Anesthesia

Iran, Islamic Republic of
National Cancer Institute (NCI)

Active, not recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Hematopoietic and Lymphoid Cell Neoplasm | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Adult Solid Neoplasm

United States
Translational Research Center for Medical Innovation...
Hiroshima Prefectural Hospital; National Hospital Organization Shikoku Cancer...

Completed

Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (BeTRI)

Metastatic Colorectal Cancer

Japan
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Gynecologic Oncology Group
National Cancer Institute (NCI); Medical Research Council; Southwest Oncology...

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditions

United States
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico, Australia, Israel, Korea, Republic of, Romania, Serbia, Spain, Taiwan
Genmab
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Cervical Small Cell Carcinoma | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer

United States
University of Washington
Genentech, Inc.

Recruiting

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

Ewing Sarcoma of Bone | Peripheral Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Extraosseous Ewing Sarcoma

United States
Rush University Medical Center

Terminated

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) (DLBCL)

Diffuse Large B-Cell Lymphoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Advanced Solid Tumors

China, United States, Australia, Canada, Chile, Israel, Japan, Korea, Republic of, Panama, Poland, Spain, Switzerland, Turkey, New Zealand, Taiwan, Denmark
City of Hope Medical Center

Active, not recruiting

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Unspecified Childhood Solid Tumor, Protocol Specific | Solid Tumor | Ewing Sarcoma | Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Adult Brain Tumor | Recurrent... and other conditions

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

Recurrent Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Ewing Sarcoma of Bone | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Neuroblastoma

United States, Canada, Australia, Puerto Rico, New Zealand, Netherlands
Baylor College of Medicine
M.D. Anderson Cancer Center; The Methodist Hospital Research Institute; Center...

Completed

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN)

Nasopharyngeal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States, Israel
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Stage III Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Adult Malignant Mesenchymoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Embryonal-botryoid Childhood Rhabdomyosarcoma | Previously... and other conditions

United States
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Suspended

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Non-Malignant Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Ewing Sarcoma of Bone | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) and other conditions

United States
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
University of Washington

Not yet recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal Zone Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Pancreatic Adenocarcinoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular Lymphoma | Refractory Grade 2 Follicular Lymphoma | Refractory Grade 3a Follicular Lymphoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer

United States

Search clinical trials for: 10E8.4/iMab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations